[{"Assets_0_Q3_USD":1669334000.0,"EarningsPerShareBasic_1_Q3_USD":0.81,"EarningsPerShareBasic_3_Q3_USD":2.56,"EarningsPerShareDiluted_1_Q3_USD":0.79,"EarningsPerShareDiluted_3_Q3_USD":2.51,"NetIncomeLoss_1_Q3_USD":70511000.0,"NetIncomeLoss_3_Q3_USD":224887000.0,"StockholdersEquity_0_Q3_USD":-48622000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":89256000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":89735000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":87537000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":87884000.0,"Ticker":"IDXX","CIK":"874716","name":"IDEXX LABORATORIES INC \/DE","OfficialName":"IDEXX Laboratories Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"42180715521.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"SP500","filed":"20171031"}]